Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion (SECURE)
This form is to be completed by a health care professional caring for a patient with psoriasis and documented coronavirus (COVID-19). Please report only confirmed COVID-19 cases, and report after a minimum of 7 days or after sufficient time has passed to observe the disease course through resolution of acute illness or death.
If you have any questions, please reach out to COVID_PSO@wakehealth.edu
Thank you!
Email address of reporter
Name of physician providing care for psoriasis
Name of center/practice providing care for psoriasis
Åland Islands Afghanistan Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Plurinational State of Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Côte dIvoire Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo the Democratic Republic of the Cook Islands Costa Rica Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic Peoples Republic of Korea, Republic of Kuwait Kyrgyzstan Lao Peoples Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Ré union Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe --- Not in this country list ---
Alabama Alaska American Samoa Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming
Female
Male
Other
Race (may check more than one)
Please specify other race
Hispanic/Latino
Not Hispanic/Latino
Unknown/Chose not to answer
Specify units for patient height
cm feet and inches height unknown
0 1 2 3 4 5 6 7
1 2 3 4 5 6 7 8 9 10 11
plaque pustular guttate intertriginous palmoplantar other unknown/unspecified
Please specify other psoriasis diagnosis
Psoriasis severity at time of COVID-19 infection (Physician Global Assessment of average lesion character), if known
Clear Almost clear Mild Moderate Severe Unknown
Estimated body surface area affected (%) (1 palm = 1%)
Psoriasis medications at time of COVID diagnosis (please include medications stopped within two weeks of time of diagnosis). Indicate all that apply.
Specify etanercept dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify etanercept dose (mg/kg)
Specify etanercept dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify adalimumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify adalimumab dose (mg/kg)
Specify adalimumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify infliximab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify infliximab dose (mg/kg)
Specify infliximab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify certolizmuab pegol dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify certolizumab pegol dose (mg/kg)
Specify certolizumab pegol dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify golimumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify golimumab dose (mg/kg)
Specify golimumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify ixekizumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify ixekizumab dose (mg/kg)
Specify ixekizumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify secukinumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify secukinumab dose (mg/kg)
Specify secukinumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify brodalumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify brodalumab dose (mg/kg)
Specify brodalumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify ustekinumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify ustekinumab dose (mg/kg)
Specify ustekinumab dosing interval (round to nearest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify guselkumab dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify guselkumab dose (mg/kg)
Specify guselkumab dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify tildrakizumab-asmn dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify tildrakizumab-asmn dose (mg/kg)
Specify tildrakizumab-asmn dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify risankizumab-rzaa dose (mg) (if prefer to answer in mg/kg skip to next question)
Specify risankizumab-rzaa dose (mg/kg)
Specify risnakizumab-rzaa dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify apremilast dose (mg)
Specify apremilast dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify methotrexate dose (mg)
Specify methotrexate dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify acitretin dose (mg)
Specify acitretin dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify cyclosporine dose (mg)
Specify cyclosporine dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify budesonide dose (mg)
Specify budesonide dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify prednisone/prednisolone dose (mg)
Specify prednisone/prednisolone dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
specify IV corticosteroid dose (mg)
Specify IV corticosteroid dosing interval (round to the nearest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify tofacitinib dose (mg)
Specify tofacitinib dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Name of topical medication
Specify topical medication dosing interval (round to closest interval)
As needed Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify phototherapy dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Specify other medication dose (mg)
Specify other medication dosing interval (round to closest interval)
Daily (includes daily and > once daily) Greater than daily but less than weekly Weekly Q2 weeks Q3 weeks Q4 weeks Q5 weeks Q6 weeks Q7 weeks Q8 weeks Q9 weeks Q10 weeks
Were any of the previously specified psoriasis medications stopped due to COVID-19 ?
yes
no
Specify psoriasis medications that were stopped due to COVID 19 (check all that apply)
Enbrel (etanercept) Humira (adalimumab) Remicade (infliximab) Cimzia (certolizumab pegol) Simponi (golimumab) Taltz (ixekizumab) Cosentyx (secukinumab) Siliq (brodalumab) Stelara (ustekinumab) Tremfya (guselkumab) Ilumya (tildrakizumab-asmn) Skyrizi (risankizumab-rzaa) Otezla (apremilast) Methotrexate Acitretin Cyclosporine Budesonide Prednisone/prednisolone Intravenous corticosteroid formulation JAK inhibitors (tofacitinib) Topical medication Phototherapy Other
Specify other medication that was stopped due to COVID 19
Does the patient have any of the following comorbidities? (Check all that apply)
Specify other relevant comorbidity
Is the patient a current cigarette smoker?
Yes
No
Unknown
Does the patient currently use alcohol?
Yes
No
Unknown
Does the patient currently use illicit drugs?
Yes
No
Unknown
Year of diagnosis of COVID-19
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040
Specify approximate number of days of symptoms from COVID-19 (if known)
Have patient's symptoms resolved at the time of this report?
Yes
No
Unknown
Patient never developed symptoms (just tested positive)
Did the patient develop new psoriasis symptoms at the time of COVID-19 infection?
Yes
No
Unknown
What were the patient's skin/psoriatic symptoms at the time of COVID 19 infection?
Specify other new skin/psoriatic symptom at the time of COVID-19 infection
Was the patient in contact with a known COVID-19 positive individual prior to their diagnosis?
Yes
No
Unknown
Did the patient travel internationally or domestically in the month prior to their diagnosis?
Yes
No
Unknown
Were any medications and/or investigational therapies used to treat COVID-19 in this patient?
Specify other medication/investigational therapy used to treat COVID-19 in this patient
Did the patient die of COVID-19 or other complications caused by or contributed to by COVID-19
Yes
No
Unknown
NOTICE: You have reported that the patient died of COVID-19 or other complications caused by or contributed to by COVID-19. If this is accurate, please confirm here. If this is not accurate, please adjust your answer above.
* must provide value
I confirm that the patient died of COVID-19 or other complications caused by or contributed to by COVID-19.
Was the patient evaluated in a hospital ER?
Yes
No
Unknown
Has the patient been hospitalized?
Yes
No
Unknown
Did patient require a ventilator?
Yes
No
Unknown
Did patient require admission to an intensive care unit (including step-down units)?
Yes
No
Unknown
Do you also enter data into any of the following patient registries? (check all that apply)
Please specify other registry name and country
We truly appreciate the time you have taken out of your busy schedule to report a case during this global crisis. We would like to acknowledge your contribution. Please check this box ONLY IF YOU WOULD LIKE TO OPT-OUT of being included in future publication acknowledgments and in the Reporter Acknowledgments section of our website (www.covidpso.org). The listing would include both reporter and physician names.
I would like to OPT-OUT of being included in future publication acknowledgments and in the Reporter Acknowledgments section of the website (www.covidpso.org).